nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CTSG—seminal vesicle—rectum cancer	0.0233	0.0332	CbGeAlD
Bortezomib—PSMA1—epithelium—rectum cancer	0.0194	0.0277	CbGeAlD
Bortezomib—PSMD1—seminal vesicle—rectum cancer	0.0187	0.0268	CbGeAlD
Bortezomib—CTSG—urethra—rectum cancer	0.0184	0.0263	CbGeAlD
Bortezomib—PSMA1—renal system—rectum cancer	0.018	0.0257	CbGeAlD
Bortezomib—CTSG—mammalian vulva—rectum cancer	0.0175	0.025	CbGeAlD
Bortezomib—PSMD2—seminal vesicle—rectum cancer	0.0166	0.0237	CbGeAlD
Bortezomib—PSMB8—seminal vesicle—rectum cancer	0.0165	0.0236	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—rectum cancer	0.0157	0.0224	CbGeAlD
Bortezomib—PSMD1—urethra—rectum cancer	0.0148	0.0212	CbGeAlD
Bortezomib—PSMB5—seminal vesicle—rectum cancer	0.0146	0.0208	CbGeAlD
Bortezomib—PSMA1—female reproductive system—rectum cancer	0.0144	0.0206	CbGeAlD
Bortezomib—PSMD1—mammalian vulva—rectum cancer	0.0141	0.0202	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—rectum cancer	0.0139	0.0199	CbGeAlD
Bortezomib—CTSG—vagina—rectum cancer	0.0136	0.0194	CbGeAlD
Bortezomib—PSMD2—renal system—rectum cancer	0.0134	0.0191	CbGeAlD
Bortezomib—PSMD2—urethra—rectum cancer	0.0131	0.0188	CbGeAlD
Bortezomib—PSMB8—urethra—rectum cancer	0.0131	0.0187	CbGeAlD
Bortezomib—PSMB1—seminal vesicle—rectum cancer	0.0127	0.0182	CbGeAlD
Bortezomib—PSMD2—mammalian vulva—rectum cancer	0.0125	0.0179	CbGeAlD
Bortezomib—PSMB8—mammalian vulva—rectum cancer	0.0124	0.0178	CbGeAlD
Bortezomib—PSMB2—seminal vesicle—rectum cancer	0.0124	0.0178	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—rectum cancer	0.0122	0.0174	CbGeAlD
Bortezomib—PSMB5—urethra—rectum cancer	0.0115	0.0165	CbGeAlD
Bortezomib—PSMB5—mammalian vulva—rectum cancer	0.011	0.0157	CbGeAlD
Bortezomib—PSMD1—vagina—rectum cancer	0.0109	0.0156	CbGeAlD
Bortezomib—SLC31A1—seminal vesicle—rectum cancer	0.0108	0.0154	CbGeAlD
Bortezomib—PSMD2—female reproductive system—rectum cancer	0.0107	0.0153	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—rectum cancer	0.0107	0.0152	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—rectum cancer	0.0104	0.0149	CbGeAlD
Bortezomib—PSMB1—renal system—rectum cancer	0.0103	0.0147	CbGeAlD
Bortezomib—PSMB1—urethra—rectum cancer	0.0101	0.0144	CbGeAlD
Bortezomib—PSMB2—renal system—rectum cancer	0.01	0.0143	CbGeAlD
Bortezomib—PSMB2—urethra—rectum cancer	0.00984	0.0141	CbGeAlD
Bortezomib—PSMD2—vagina—rectum cancer	0.00969	0.0138	CbGeAlD
Bortezomib—PSMB8—vagina—rectum cancer	0.00963	0.0138	CbGeAlD
Bortezomib—PSMB1—mammalian vulva—rectum cancer	0.0096	0.0137	CbGeAlD
Bortezomib—PSMB2—mammalian vulva—rectum cancer	0.00937	0.0134	CbGeAlD
Bortezomib—CTSG—lymph node—rectum cancer	0.00878	0.0125	CbGeAlD
Bortezomib—SLC31A1—renal system—rectum cancer	0.00868	0.0124	CbGeAlD
Bortezomib—SLC31A1—urethra—rectum cancer	0.00852	0.0122	CbGeAlD
Bortezomib—PSMB5—vagina—rectum cancer	0.00851	0.0122	CbGeAlD
Bortezomib—PSMA1—lymph node—rectum cancer	0.00843	0.012	CbGeAlD
Bortezomib—PSMB1—female reproductive system—rectum cancer	0.00823	0.0117	CbGeAlD
Bortezomib—SLC31A1—mammalian vulva—rectum cancer	0.00812	0.0116	CbGeAlD
Bortezomib—PSMB2—female reproductive system—rectum cancer	0.00803	0.0115	CbGeAlD
Bortezomib—PSMB1—vagina—rectum cancer	0.00744	0.0106	CbGeAlD
Bortezomib—PSMB2—vagina—rectum cancer	0.00726	0.0104	CbGeAlD
Bortezomib—PSMD1—lymph node—rectum cancer	0.00708	0.0101	CbGeAlD
Bortezomib—SLC31A1—female reproductive system—rectum cancer	0.00695	0.00992	CbGeAlD
Bortezomib—SLC31A1—vagina—rectum cancer	0.00629	0.00897	CbGeAlD
Bortezomib—PSMD2—lymph node—rectum cancer	0.00627	0.00895	CbGeAlD
Bortezomib—PSMB8—lymph node—rectum cancer	0.00623	0.0089	CbGeAlD
Bortezomib—PSMB5—lymph node—rectum cancer	0.0055	0.00786	CbGeAlD
Bortezomib—PSMB1—lymph node—rectum cancer	0.00481	0.00687	CbGeAlD
Bortezomib—PSMB2—lymph node—rectum cancer	0.00469	0.0067	CbGeAlD
Bortezomib—SLC31A1—lymph node—rectum cancer	0.00407	0.00581	CbGeAlD
Bortezomib—PSMD2—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.0036	0.012	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—RAB1A—rectum cancer	0.00325	0.0108	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—RAB1A—rectum cancer	0.00323	0.0108	CbGpPWpGaD
Bortezomib—SLC31A1—Copper homeostasis—TP53—rectum cancer	0.00323	0.0108	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—RAB1A—rectum cancer	0.00322	0.0107	CbGpPWpGaD
Bortezomib—PTGS1—seminal vesicle—rectum cancer	0.00321	0.00459	CbGeAlD
Bortezomib—CYP2C8—renal system—rectum cancer	0.00319	0.00456	CbGeAlD
Bortezomib—CYP1A1—epithelium—rectum cancer	0.00318	0.00454	CbGeAlD
Bortezomib—PSMA1—G1/S Transition—TYMS—rectum cancer	0.00305	0.0102	CbGpPWpGaD
Bortezomib—PSMD1—G1/S Transition—TYMS—rectum cancer	0.00304	0.0101	CbGpPWpGaD
Bortezomib—PSMD2—G1/S Transition—TYMS—rectum cancer	0.00302	0.0101	CbGpPWpGaD
Bortezomib—CYP1A2—renal system—rectum cancer	0.00299	0.00427	CbGeAlD
Bortezomib—CYP1A1—renal system—rectum cancer	0.00295	0.00421	CbGeAlD
Bortezomib—CYP1A1—urethra—rectum cancer	0.0029	0.00413	CbGeAlD
Bortezomib—PTGS1—epithelium—rectum cancer	0.00279	0.00399	CbGeAlD
Bortezomib—CYP1A1—mammalian vulva—rectum cancer	0.00276	0.00394	CbGeAlD
Bortezomib—PSMB2—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00275	0.00919	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00275	0.00919	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00275	0.00919	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00272	0.00906	CbGpPWpGaD
Bortezomib—PTGS1—smooth muscle tissue—rectum cancer	0.00269	0.00384	CbGeAlD
Bortezomib—CYP2C19—vagina—rectum cancer	0.00265	0.00378	CbGeAlD
Bortezomib—PTGS1—renal system—rectum cancer	0.00259	0.0037	CbGeAlD
Bortezomib—PSMA1—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00257	0.00858	CbGpPWpGaD
Bortezomib—PSMD1—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00256	0.00854	CbGpPWpGaD
Bortezomib—CYP2C8—female reproductive system—rectum cancer	0.00256	0.00365	CbGeAlD
Bortezomib—PSMD2—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00255	0.0085	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—RAB1A—rectum cancer	0.00246	0.00822	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—RAB1A—rectum cancer	0.00246	0.00822	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—RAB1A—rectum cancer	0.00246	0.00822	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—RAB1A—rectum cancer	0.00243	0.0081	CbGpPWpGaD
Bortezomib—PTGS1—mammalian vulva—rectum cancer	0.00242	0.00346	CbGeAlD
Bortezomib—CYP1A1—female reproductive system—rectum cancer	0.00236	0.00337	CbGeAlD
Bortezomib—PSMB1—G1/S Transition—TYMS—rectum cancer	0.00231	0.00772	CbGpPWpGaD
Bortezomib—PSMB5—G1/S Transition—TYMS—rectum cancer	0.00231	0.00772	CbGpPWpGaD
Bortezomib—PSMB2—G1/S Transition—TYMS—rectum cancer	0.00231	0.00772	CbGpPWpGaD
Bortezomib—CYP2C8—vagina—rectum cancer	0.00231	0.0033	CbGeAlD
Bortezomib—PSMB8—G1/S Transition—TYMS—rectum cancer	0.00228	0.00761	CbGpPWpGaD
Bortezomib—CYP2C9—female reproductive system—rectum cancer	0.00227	0.00324	CbGeAlD
Bortezomib—CYP3A4—renal system—rectum cancer	0.00216	0.00309	CbGeAlD
Bortezomib—CYP1A1—vagina—rectum cancer	0.00213	0.00305	CbGeAlD
Bortezomib—CYP2D6—renal system—rectum cancer	0.00213	0.00304	CbGeAlD
Bortezomib—PTGS1—female reproductive system—rectum cancer	0.00207	0.00296	CbGeAlD
Bortezomib—PSMB1—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00195	0.0065	CbGpPWpGaD
Bortezomib—PSMB2—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00195	0.0065	CbGpPWpGaD
Bortezomib—PSMB5—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00195	0.0065	CbGpPWpGaD
Bortezomib—PSMB8—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00192	0.00641	CbGpPWpGaD
Bortezomib—PSMA1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00189	0.0063	CbGpPWpGaD
Bortezomib—PSMD1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00188	0.00627	CbGpPWpGaD
Bortezomib—PTGS1—vagina—rectum cancer	0.00188	0.00268	CbGeAlD
Bortezomib—PSMD2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00187	0.00624	CbGpPWpGaD
Bortezomib—PSMA1—Stabilization of p53—TP53—rectum cancer	0.00186	0.0062	CbGpPWpGaD
Bortezomib—PSMD1—Stabilization of p53—TP53—rectum cancer	0.00185	0.00617	CbGpPWpGaD
Bortezomib—PSMD2—Stabilization of p53—TP53—rectum cancer	0.00184	0.00614	CbGpPWpGaD
Bortezomib—CYP3A4—female reproductive system—rectum cancer	0.00173	0.00247	CbGeAlD
Bortezomib—PSMA1—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00172	0.00575	CbGpPWpGaD
Bortezomib—PSMD1—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00172	0.00573	CbGpPWpGaD
Bortezomib—PSMD2—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00171	0.0057	CbGpPWpGaD
Bortezomib—CYP2D6—female reproductive system—rectum cancer	0.0017	0.00243	CbGeAlD
Bortezomib—PSMA1—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00165	0.00552	CbGpPWpGaD
Bortezomib—PSMD1—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00165	0.00549	CbGpPWpGaD
Bortezomib—PSMD2—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00164	0.00547	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—NRAS—rectum cancer	0.0015	0.00501	CbGpPWpGaD
Bortezomib—PSMB5—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00143	0.00478	CbGpPWpGaD
Bortezomib—PSMB1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00143	0.00478	CbGpPWpGaD
Bortezomib—PSMB2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00143	0.00478	CbGpPWpGaD
Bortezomib—PSMB8—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00141	0.00471	CbGpPWpGaD
Bortezomib—PSMB2—Stabilization of p53—TP53—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Bortezomib—PSMB5—Stabilization of p53—TP53—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Bortezomib—PSMB1—Stabilization of p53—TP53—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Bortezomib—PSMB8—Stabilization of p53—TP53—rectum cancer	0.00139	0.00463	CbGpPWpGaD
Bortezomib—CYP1A1—lymph node—rectum cancer	0.00138	0.00197	CbGeAlD
Bortezomib—PSMB5—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00131	0.00436	CbGpPWpGaD
Bortezomib—PSMB1—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00131	0.00436	CbGpPWpGaD
Bortezomib—PSMB2—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00131	0.00436	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—KRAS—rectum cancer	0.00129	0.00431	CbGpPWpGaD
Bortezomib—PSMB8—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00129	0.0043	CbGpPWpGaD
Bortezomib—PSMB2—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00125	0.00418	CbGpPWpGaD
Bortezomib—PSMB1—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00125	0.00418	CbGpPWpGaD
Bortezomib—PSMB5—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00125	0.00418	CbGpPWpGaD
Bortezomib—PSMB8—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00124	0.00412	CbGpPWpGaD
Bortezomib—PTGS1—lymph node—rectum cancer	0.00121	0.00173	CbGeAlD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—HRAS—rectum cancer	0.0011	0.00366	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle Checkpoints—TP53—rectum cancer	0.000956	0.00319	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle Checkpoints—TP53—rectum cancer	0.000952	0.00318	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle Checkpoints—TP53—rectum cancer	0.000947	0.00316	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000943	0.00315	CbGpPWpGaD
Bortezomib—PSMA1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000941	0.00314	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000939	0.00313	CbGpPWpGaD
Bortezomib—PSMD1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000936	0.00312	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000934	0.00312	CbGpPWpGaD
Bortezomib—PSMD2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000932	0.00311	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TYMS—rectum cancer	0.000843	0.00281	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TYMS—rectum cancer	0.000839	0.0028	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TYMS—rectum cancer	0.000835	0.00279	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—NRAS—rectum cancer	0.000831	0.00277	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—NRAS—rectum cancer	0.000827	0.00276	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—NRAS—rectum cancer	0.000823	0.00275	CbGpPWpGaD
Bortezomib—PSMA1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00081	0.0027	CbGpPWpGaD
Bortezomib—PSMD1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000806	0.00269	CbGpPWpGaD
Bortezomib—PSMD2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000802	0.00268	CbGpPWpGaD
Bortezomib—PSMA1—Apoptosis—TP53—rectum cancer	0.000764	0.00255	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TP53—rectum cancer	0.00076	0.00254	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TP53—rectum cancer	0.000756	0.00252	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000737	0.00246	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle Checkpoints—TP53—rectum cancer	0.000725	0.00242	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle Checkpoints—TP53—rectum cancer	0.000725	0.00242	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle Checkpoints—TP53—rectum cancer	0.000725	0.00242	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—KRAS—rectum cancer	0.000715	0.00239	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000715	0.00239	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000715	0.00239	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000715	0.00239	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle Checkpoints—TP53—rectum cancer	0.000715	0.00238	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000713	0.00238	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000713	0.00238	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000713	0.00238	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—KRAS—rectum cancer	0.000712	0.00238	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—KRAS—rectum cancer	0.000708	0.00236	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—TYMS—rectum cancer	0.000705	0.00235	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000703	0.00235	CbGpPWpGaD
Bortezomib—PSMA1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000688	0.0023	CbGpPWpGaD
Bortezomib—PSMD1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000685	0.00229	CbGpPWpGaD
Bortezomib—PSMD2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000682	0.00227	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TYMS—rectum cancer	0.000639	0.00213	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TYMS—rectum cancer	0.000639	0.00213	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TYMS—rectum cancer	0.000639	0.00213	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000634	0.00212	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TYMS—rectum cancer	0.00063	0.0021	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—NRAS—rectum cancer	0.00063	0.0021	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—NRAS—rectum cancer	0.00063	0.0021	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—NRAS—rectum cancer	0.00063	0.0021	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—NRAS—rectum cancer	0.000621	0.00207	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000614	0.00205	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000614	0.00205	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000614	0.00205	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—HRAS—rectum cancer	0.000608	0.00203	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—HRAS—rectum cancer	0.000605	0.00202	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000605	0.00202	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—HRAS—rectum cancer	0.000602	0.00201	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TP53—rectum cancer	0.000579	0.00193	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TP53—rectum cancer	0.000579	0.00193	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TP53—rectum cancer	0.000579	0.00193	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TP53—rectum cancer	0.000571	0.0019	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—KRAS—rectum cancer	0.000542	0.00181	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—KRAS—rectum cancer	0.000542	0.00181	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—KRAS—rectum cancer	0.000542	0.00181	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000539	0.0018	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—KRAS—rectum cancer	0.000534	0.00178	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000521	0.00174	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000521	0.00174	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000521	0.00174	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000514	0.00172	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.00047	0.00157	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000465	0.00155	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—HRAS—rectum cancer	0.000461	0.00154	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—HRAS—rectum cancer	0.000461	0.00154	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—HRAS—rectum cancer	0.000461	0.00154	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—HRAS—rectum cancer	0.000454	0.00152	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000404	0.00135	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.0004	0.00134	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—TYMS—rectum cancer	0.000362	0.00121	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—TYMS—rectum cancer	0.000361	0.0012	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—TYMS—rectum cancer	0.000359	0.0012	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000344	0.00115	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.00034	0.00113	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—NRAS—rectum cancer	0.000335	0.00112	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—NRAS—rectum cancer	0.000333	0.00111	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—NRAS—rectum cancer	0.000332	0.00111	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—KRAS—rectum cancer	0.000288	0.000962	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KRAS—rectum cancer	0.000287	0.000958	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KRAS—rectum cancer	0.000286	0.000953	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—rectum cancer	0.00028	0.000933	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—rectum cancer	0.000278	0.000929	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—rectum cancer	0.000277	0.000925	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—TYMS—rectum cancer	0.000275	0.000916	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—TYMS—rectum cancer	0.000275	0.000916	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—TYMS—rectum cancer	0.000275	0.000916	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—TYMS—rectum cancer	0.000271	0.000903	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—NRAS—rectum cancer	0.000254	0.000847	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—NRAS—rectum cancer	0.000254	0.000847	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—NRAS—rectum cancer	0.000254	0.000847	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—NRAS—rectum cancer	0.00025	0.000835	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HRAS—rectum cancer	0.000245	0.000818	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HRAS—rectum cancer	0.000244	0.000814	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—rectum cancer	0.000243	0.00081	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KRAS—rectum cancer	0.000218	0.000729	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KRAS—rectum cancer	0.000218	0.000729	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KRAS—rectum cancer	0.000218	0.000729	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KRAS—rectum cancer	0.000215	0.000719	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—rectum cancer	0.000212	0.000707	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—rectum cancer	0.000212	0.000707	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—rectum cancer	0.000212	0.000707	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—rectum cancer	0.000209	0.000697	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NRAS—rectum cancer	0.000203	0.000678	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NRAS—rectum cancer	0.000202	0.000675	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NRAS—rectum cancer	0.000201	0.000672	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—rectum cancer	0.000188	0.000626	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—rectum cancer	0.000187	0.000623	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—rectum cancer	0.000186	0.00062	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—rectum cancer	0.000186	0.00062	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—rectum cancer	0.000186	0.00062	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—rectum cancer	0.000186	0.00062	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—rectum cancer	0.000183	0.000611	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KRAS—rectum cancer	0.000175	0.000584	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KRAS—rectum cancer	0.000174	0.000581	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KRAS—rectum cancer	0.000173	0.000578	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KRAS—rectum cancer	0.000161	0.000539	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KRAS—rectum cancer	0.000161	0.000536	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KRAS—rectum cancer	0.00016	0.000534	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—rectum cancer	0.000154	0.000514	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—rectum cancer	0.000154	0.000514	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—rectum cancer	0.000154	0.000514	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NRAS—rectum cancer	0.000152	0.000507	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—rectum cancer	0.000149	0.000496	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—rectum cancer	0.000148	0.000494	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—rectum cancer	0.000147	0.000491	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—TYMS—rectum cancer	0.000144	0.000479	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—rectum cancer	0.000142	0.000474	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—rectum cancer	0.000142	0.000474	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—rectum cancer	0.000142	0.000474	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—rectum cancer	0.00014	0.000468	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—rectum cancer	0.000137	0.000458	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—rectum cancer	0.000137	0.000456	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—rectum cancer	0.000136	0.000454	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—rectum cancer	0.000133	0.000442	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—rectum cancer	0.000133	0.000442	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—rectum cancer	0.000133	0.000442	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—rectum cancer	0.000131	0.000438	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—rectum cancer	0.000131	0.000436	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—rectum cancer	0.000131	0.000436	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—rectum cancer	0.00013	0.000434	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—rectum cancer	0.000122	0.000408	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—rectum cancer	0.000122	0.000408	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—rectum cancer	0.000122	0.000408	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—rectum cancer	0.000121	0.000403	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—rectum cancer	0.000113	0.000377	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—rectum cancer	0.000113	0.000376	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—rectum cancer	0.000113	0.000376	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—rectum cancer	0.000113	0.000376	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—rectum cancer	0.000113	0.000376	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—rectum cancer	0.000112	0.000374	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—rectum cancer	0.000111	0.000371	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—rectum cancer	0.000104	0.000347	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—rectum cancer	0.000104	0.000347	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—rectum cancer	0.000104	0.000347	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—rectum cancer	0.000103	0.000342	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—rectum cancer	0.000101	0.000338	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—rectum cancer	0.0001	0.000335	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—rectum cancer	0.0001	0.000334	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—rectum cancer	9.96e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—rectum cancer	9.96e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—rectum cancer	9.96e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—rectum cancer	9.95e-05	0.000332	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—rectum cancer	9.81e-05	0.000328	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—rectum cancer	9.61e-05	0.000321	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—rectum cancer	9.56e-05	0.000319	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—rectum cancer	9.52e-05	0.000318	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—rectum cancer	9.27e-05	0.000309	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—rectum cancer	8.57e-05	0.000286	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—rectum cancer	8.57e-05	0.000286	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—rectum cancer	8.57e-05	0.000286	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—rectum cancer	8.45e-05	0.000282	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—rectum cancer	8.28e-05	0.000276	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—rectum cancer	7.62e-05	0.000254	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—rectum cancer	7.62e-05	0.000254	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—rectum cancer	7.62e-05	0.000254	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—rectum cancer	7.61e-05	0.000254	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—rectum cancer	7.55e-05	0.000252	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—rectum cancer	7.51e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—rectum cancer	7.28e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—rectum cancer	7.28e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—rectum cancer	7.28e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—rectum cancer	7.18e-05	0.00024	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—rectum cancer	6.45e-05	0.000215	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—rectum cancer	4.98e-05	0.000166	CbGpPWpGaD
